Humacyte, Inc.
HUMA
Rank in Stocks
#18646
Humacyte, Inc. focuses on developing and manufacturing readily available,... Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Share Price
$0.4552
Last synced: 2026-11-09
Market Cap
$126.45M
Change (1 day)
1.56%
Change (1 year)
-64.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Humacyte, Inc. (HUMA)
Category
Healthcare
Operating Margin for Humacyte, Inc. (HUMA)
Operating Margin as of November 2026 TTM: -5,240.78%
According to Humacyte, Inc.'s latest financial reports, its current operating margin (TTM) is -5,240.78%. At the end of 2025 the company had an operating margin of -5,271.69%.
Operating Margin history for Humacyte, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -5,240.78% | -0.59% |
| 2025 | -5,271.69% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -5,404.35% | -15.95% |
| 2021 | -6,429.77% | 48.40% |
| 2020 | -4,332.66% | 212.82% |
| 2019 | -1,385.02% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.97% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Humacyte, Inc.'s operating margin
What is Humacyte, Inc.'s operating margin?
Humacyte, Inc.'s operating margin is -5,240.78%, as of Nov 2026.
What was Humacyte, Inc.'s operating margin in 2025?
In 2025, Humacyte, Inc.'s operating margin was -5,271.69%, compared with 0.00% in 2024.
How has Humacyte, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Humacyte, Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2021 (-6,429.77%).
How does Humacyte, Inc.'s operating margin compare with similar companies?
Humacyte, Inc.'s operating margin (-5,240.78%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.